Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Asarina Pharma AB (publ)
  6. Summary
    ASAP   SE0011641794

ASARINA PHARMA AB (PUBL)

(ASAP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
11/23/2021 11/24/2021 11/25/2021 11/26/2021 11/29/2021 Date
2.165(c) 2.04(c) 2.02(c) 1.876(c) 1.988 Last
34 081 13 751 23 423 12 589 76 688 Volume
-1.14% -5.77% -0.98% -7.13% +5.97% Change
More quotes
Estimated financial data (e)
Sales 2019 - - -
Net income 2019 -71,1 M -7,80 M -7,80 M
Net cash position 2019 130 M 14,2 M 14,2 M
P/E ratio 2019 -5,70x
Yield 2019 -
Sales 2020 - - -
Net income 2020 -75,3 M -8,25 M -8,25 M
Net cash position 2020 58,5 M 6,42 M 6,42 M
P/E ratio 2020 -1,50x
Yield 2020 -
Capitalization 35,2 M 3,86 M 3,86 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 4
Free-Float 74,9%
More Financials
Company
Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of women’s health. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. 
More about the company
All news about ASARINA PHARMA AB (PUBL)
11/25Asarina Pharma AB (publ) Q3 Report 2021 released
AQ
11/25Asarina Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
09/29ASARINA PHARMA : PMDD Phase IIb study, including post-hoc analysis showing 'significant tr..
AQ
09/28ASARINA PHARMA : PMDD Phase IIb study, including post-hoc analysis showing `significant tr..
AQ
09/28Pmdd Phase Iib Study, Including Post-Hoc Analysis Showing ‘Significant Treatment Effect
CI
09/16ASARINA PHARMA : Administrative backlog at public authority causes short-term delay in Tou..
AQ
09/16Asarina Pharma Announces Administrative Backlog At Public Authority Causes Short-Term D..
CI
08/19ASARINA PHARMA AB : (publ) Q2 Report 2021 released
AQ
08/19Asarina Pharma AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2..
CI
06/23ASARINA PHARMA : reports topline results in Phase IIa Menstrual Migraine study
AQ
06/23Asarina Pharma Reports Topline Results in Phase IIa Menstrual Migraine Study
CI
06/08ASARINA PHARMA : granted US patent for Sepranolone for Tourette syndrome, OCD and patholog..
AQ
06/08The US Patent and Trademark Office Grants Asarina Pharma's Patent for Sepranolone for t..
CI
05/31ASARINA PHARMA : obtains convertible loan for continued research on neurological condition..
AQ
05/31ASARINA PHARMA : Issuance of 700,000 warrants completed
AQ
More news
News in other languages on ASARINA PHARMA AB (PUBL)

- No features available -

More news
Chart ASARINA PHARMA AB (PUBL)
Duration : Period :
Asarina Pharma AB (publ) Technical Analysis Chart | ASAP | SE0011641794 | MarketScreener
Technical analysis trends ASARINA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 1,88 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Peter Nordkild Chief Executive Officer
Jakob Dynnes Hansen Chief Financial Officer
Paul de Potocki Chairman
Märta Segerdahl Chief Medical Officer
Magnus Brisander Principal Scientist
Sector and Competitors
1st jan.Capi. (M$)
ASARINA PHARMA AB (PUBL)-68.94%4
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678